Osborn McDerby successfully represented and advised the lead investor, Partner Fund Management, in Allena Pharmaceuticals, Inc.’s $53M Series C preferred stock financing. Allena Pharmaceuticals, a protein-therapy pharmaceutical company, intends to use the proceeds from the financing to further develop its lead product candidate, ALLN-177.
Osborn McDerby’s experience with complex transactions allows us to keep current on market terms and trends, as we continue to grow our venture capital and private equity practice. The principal attorneys representing Partner Fund Management were Steve Osborn and Chris Dayans.
To read Allena’s press release, click here.